Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Pemetrexed and Cisplatin Induction and Concurrent Chemoradiotherapy in Unresectable Stage III Non-squamous NSCLC
2009-011739-11Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: 1-year progression-free survival. Started Jun 2009; status: completed.
02
Drugs
pemetrexedcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-011739-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011739-11.